IMU
Click for more information
0.00% 5.4¢ imugene limited

Herceptin patent

  1. eugened
    1,300 Posts.
    lightbulb Created with Sketch. 218
    clock Created with Sketch.
    14/03/16
    22:07
    Post #: 17272812
    The patent for trastuzumab (Herceptin) has expired in Europe and will expire in the US in 2019. There are a number of companies who are now making trastuzumab biosimilars, eg. Celltrion in Korea and Biocad in Russia - so expect the price to drop.

    An advantage of the treatment combining both Herceptin and Tyverbis is that the two drugs cost
    IMU Price at posting: 1.0¢ Sentiment: None Disclosure: Not Held
    Likes Created with Sketch.  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

HAR Haranga Resources reports significant resource upgrade at Saraya Uranium Project
right-arrow Created with Sketch.
RDN Raiden gears up for exploration in final quarter of 2024
right-arrow Created with Sketch.
NEWS Dale Gillham's weekly wrap: responding to a weak iron ore price with investing decisions
right-arrow Created with Sketch.
NEWS The business of sport: Warren Tredrea's take on this week's news
right-arrow Created with Sketch.
NEWS Why are so many ASX explorers setting up shop in Saudi Arabia? + 8 stocks to watch
right-arrow Created with Sketch.
PLS Pilbara blames low lithium prices for 89% drop in profit for FY24
right-arrow Created with Sketch.
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Last
5.4¢ 		Change
0.000(0.00%) 		Mkt cap ! $396.8M
Open High Low Value Volume
5.4¢ 5.4¢ 5.3¢ $339.4K 6.365M

Buyers (Bids)

No. Vol. Price($)
7 895592 5.3¢
 

Sellers (Offers)

Price($) Vol. No.
5.4¢ 672708 10
View Market Depth
Last trade - 16.10pm 28/08/2024 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.